Lurasidone Hydrochloride

1~8 批国采全国统一接续采购开始企业及产品申报啦！ 今日，《国家组织集采药品协议期满品种接续采购公告（第1号）》发布，按照国家医疗保障局统一部署，全国各省（自治区、直辖市）和新疆生产建设兵团组成采购联盟，委托江苏省、河南省和广东省牵头，遵循“稳临床、保质量、反内卷、防围标”原则，对原国家组织集采1-8批（不含胰岛素专项采购）协议期满的品种，开展全国统一接续采购工作。 据《公告》，本次接续采购医药机构需求量填报已完成，现启动企业及产品申报，具体目录如下（规格可点击「阅读原文」下载原始表格）： # 品种名称 1 阿托伐他汀口服常释剂型 2 瑞舒伐他汀口服常释剂型 3 氯吡格雷口服常释剂型 4 厄贝沙坦口服常释剂型 5 氨氯地平口服常释剂型 6 恩替卡韦口服常释剂型 7 艾司西酞普兰口服常释剂型 8 帕罗西汀口服常释剂型 9 奥氮平口服常释剂型 10 头孢呋辛酯（头孢呋辛）口服常释剂型 11 利培酮口服常释剂型 12 吉非替尼口服常释剂型 13 福辛普利口服常释剂型 14 厄贝沙坦氢氯噻嗪口服常释剂型 15 赖诺普利口服常释剂型 16 替诺福韦二吡呋酯口服常释剂型 17 氯沙坦口服常释剂型 18 依那普利口服常释剂型 19 左乙拉西坦口服常释剂型 20 伊马替尼口服常释剂型 21 孟鲁司特口服常释剂型 22 蒙脱石口服散剂 23 培美曲塞注射剂 24 氟比洛芬酯注射剂 25 右美托咪定注射剂 26 阿比特龙口服常释剂型 27 阿德福韦酯口服常释剂型 28 阿卡波糖口服常释剂型 29 阿莫西林口服常释剂型 30 阿奇霉素口服常释剂型 31 安立生坦片 32 奥美沙坦酯口服常释剂型 33 比索洛尔口服常释剂型 34 对乙酰氨基酚口服常释剂型 35 多奈哌齐口服常释剂型 36 氟康唑口服常释剂型 37 福多司坦口服常释剂型 38 格列美脲口服常释剂型 39 甲硝唑口服常释剂型 40 聚乙二醇口服散剂 41 坎地沙坦酯口服常释剂型 42 克林霉素口服常释剂型 43 铝碳酸镁咀嚼片 44 美洛昔康口服常释剂型 45 莫西沙星口服常释剂型 46 曲美他嗪缓释控释剂型 47 索利那新口服常释剂型 48 他达拉非片 49 特拉唑嗪口服常释剂型 50 替吉奥口服常释剂型 51 头孢氨苄口服常释剂型 52 头孢拉定口服常释剂型 53 辛伐他汀口服常释剂型 54 异烟肼口服常释剂型 55 吲达帕胺口服常释剂型 56 注射用紫杉醇（白蛋白结合型） 57 左西替利嗪口服常释剂型 58 阿那曲唑口服常释剂型 59 阿哌沙班口服常释剂型 60 阿扎胞苷注射剂 61 氨基葡萄糖口服常释剂型 62 氨溴索口服常释剂型 63 奥氮平口腔崩解片 64 奥美拉唑口服常释剂型 65 布洛芬缓释控释剂型 66 布洛芬颗粒剂 67 地氯雷他定口服常释剂型 68 多潘立酮口服常释剂型 69 二甲双胍缓释控释剂型 70 二甲双胍口服常释剂型 71 非布司他口服常释剂型 72 非那雄胺口服常释剂型 73 非那雄胺口服常释剂型 74 氟西汀口服常释剂型 75 枸橼酸西地那非片 76 甲钴胺口服常释剂型 77 卡培他滨口服常释剂型 78 卡托普利口服常释剂型 79 喹硫平口服常释剂型 80 来曲唑口服常释剂型 81 氯氮平口服常释剂型 82 美金刚口服常释剂型 83 孟鲁司特咀嚼片 84 孟鲁司特颗粒剂 85 匹伐他汀口服常释剂型 86 普芦卡必利口服常释剂型 87 曲美他嗪口服常释剂型 88 塞来昔布口服常释剂型 89 舍曲林口服常释剂型 90 坦洛新（坦索罗辛）缓释控释剂型 91 碳酸氢钠口服常释剂型 92 替格瑞洛口服常释剂型 93 托法替布口服常释剂型 94 维格列汀口服常释剂型 95 维生素B6口服常释剂型 96 西酞普兰口服常释剂型 97 西替利嗪口服常释剂型 98 缬沙坦口服常释剂型 99 盐酸达泊西汀片 100 依托考昔口服常释剂型 101 乙胺丁醇口服常释剂型 102 右佐匹克隆口服常释剂型 103 左乙拉西坦口服液体剂 104 左乙拉西坦注射用浓溶液 105 阿莫西林颗粒剂 106 利奈唑胺口服常释剂型 107 莫西沙星氯化钠注射剂 108 左氧氟沙星滴眼剂 109 环丙沙星口服常释剂型 110 头孢地尼口服常释剂型 111 头孢克洛口服常释剂型 112 克拉霉素口服常释剂型 113 埃索美拉唑（艾司奥美拉唑）口服常释剂型 114 氨磺必利口服常释剂型 115 氨溴索注射剂 116 奥洛他定滴眼剂 117 吡嗪酰胺口服常释剂型 118 丙泊酚中/长链脂肪乳注射剂 119 布洛芬口服常释剂型 120 布洛芬注射液 121 度洛西汀口服常释剂型 122 多索茶碱注射剂 123 恩格列净口服常释剂型 124 恩曲他滨替诺福韦口服常释剂型 125 格列齐特缓释控释剂型 126 加巴喷丁口服常释剂型 127 卡格列净口服常释剂型 128 喹硫平缓释控释剂型 129 洛索洛芬口服常释剂型 130 氯雷他定口服常释剂型 131 莫沙必利口服常释剂型 132 那格列奈口服常释剂型 133 帕瑞昔布注射剂 134 泮托拉唑口服常释剂型 135 泮托拉唑注射剂 136 培哚普利口服常释剂型 137 硼替佐米注射剂 138 普拉克索缓释控释剂型 139 普拉克索口服常释剂型 140 普瑞巴林口服常释剂型 141 羟苯磺酸口服常释剂型 142 瑞格列奈口服常释剂型 143 索拉非尼口服常释剂型 144 替格瑞洛口服常释剂型 145 替米沙坦口服常释剂型 146 替莫唑胺口服常释剂型 147 吸入用硫酸沙丁胺醇溶液 148 缬沙坦氨氯地平Ⅰ口服常释剂型 149 缬沙坦氢氯噻嗪口服常释剂型 150 伏立康唑口服常释剂型 151 诺氟沙星口服常释剂型 152 特比萘芬口服常释剂型 153 头孢丙烯口服常释剂型 154 左氧氟沙星口服常释剂型 155 玻璃酸钠滴眼剂 156 注射用比伐芦定 157 ω-3鱼油中/长链脂肪乳注射液 158 阿法骨化醇口服常释剂型 159 阿立哌唑口服常释剂型 160 阿昔洛韦口服常释剂型 161 埃索美拉唑（艾司奥美拉唑）注射剂 162 奥洛他定口服常释剂型 163 奥沙利铂注射剂 164 贝那普利口服常释剂型 165 贝他斯汀口服常释剂型 166 苯磺顺阿曲库铵注射剂 167 比卡鲁胺口服常释剂型 168 达比加群酯口服常释剂型 169 达比加群酯口服常释剂型 170 单硝酸异山梨酯缓释控释剂型 171 地西他滨注射剂 172 碘海醇注射剂 173 碘海醇注射剂 174 碘克沙醇注射剂 175 度他雄胺软胶囊 176 多西他赛注射剂 177 法舒地尔注射剂 178 复方异丙托溴铵吸入剂 179 格列吡嗪缓释控释剂型 180 格列吡嗪口服常释剂型 181 格隆溴铵注射液 182 更昔洛韦注射剂 183 枸橼酸氢钾钠颗粒 184 吉西他滨注射剂 185 兰索拉唑注射剂 186 乐卡地平口服常释剂型 187 利伐沙班口服常释剂型 188 利伐沙班口服常释剂型 189 利伐沙班口服常释剂型 190 硫辛酸注射剂 191 罗哌卡因注射剂 192 氯化钾缓释控释剂型 193 美托洛尔口服常释剂型 194 米格列醇口服常释剂型 195 米索前列醇口服常释剂型 196 帕洛诺司琼注射剂 197 沙格列汀口服常释剂型 198 文拉法辛缓释控释剂型 199 西那卡塞口服常释剂型 200 胸腺法新注射剂 201 异丙嗪口服常释剂型 202 异丙托溴铵吸入剂 203 脂肪乳氨基酸葡萄糖注射剂 204 中/长链脂肪乳注射剂 205 注射用盐酸苯达莫司汀 206 紫杉醇注射剂 207 阿奇霉素注射剂 208 布地奈德吸入剂 209 氟康唑注射剂型 210 利奈唑胺葡萄糖注射剂 211 莫西沙星滴眼剂 212 替硝唑口服常释剂型 213 头孢呋辛注射剂 214 头孢曲松注射剂 215 头孢他啶注射剂 216 头孢唑林注射剂型 217 左氧氟沙星注射剂型 218 阿法替尼口服常释剂型 219 阿立哌唑口腔崩解片 220 昂丹司琼注射剂 221 奥美拉唑注射剂 222 奥曲肽注射剂 223 奥司他韦口服常释剂型 224 吡格列酮口服常释剂型 225 丙酚替诺福韦口服常释剂型 226 醋酸钙口服常释剂型 227 单硝酸异山梨酯口服常释剂型 228 碘帕醇注射剂 229 厄洛替尼口服常释剂型 230 二甲双胍维格列汀口服常释剂型 231 氟桂利嗪口服常释剂型 232 氟哌噻吨美利曲辛口服常释剂型 233 磺达肝癸钠注射剂 234 甲磺酸仑伐替尼胶囊 235 咖啡因注射剂 236 拉考沙胺口服常释剂型 237 来氟米特口服常释剂型 238 利多卡因注射剂 239 罗库溴铵注射剂 240 吗替麦考酚酯口服常释剂型 241 美托洛尔缓释剂型 242 米力农注射剂 243 帕立骨化醇注射剂 244 帕洛诺司琼注射剂 245 普萘洛尔口服常释剂型 246 舒尼替尼口服常释剂型 247 特布他林吸入剂 248 替罗非班注射剂型 249 硝苯地平缓释剂型 250 硝苯地平控释剂型 251 盐酸鲁拉西酮片 252 盐酸美金刚缓释胶囊 253 伊班膦酸注射剂 254 伊立替康注射剂 255 依巴斯汀口服常释剂型 256 依达拉奉注射剂型 257 依替巴肽注射剂 258 依折麦布口服常释剂型 259 注射用替莫唑胺 260 唑来膦酸注射剂 261 唑来膦酸注射剂 262 甲泼尼龙口服常释剂型 263 甲泼尼龙注射剂 264 甲泼尼龙注射剂 265 奥硝唑口服常释剂型 266 克林霉素磷酸酯注射剂 267 罗红霉素口服常释剂型 268 头孢克洛口服液体剂 269 头孢克肟颗粒剂 270 头孢克肟口服常释剂型 271 头孢美唑注射剂型 272 头孢米诺注射剂 273 美罗培南注射剂 274 米卡芬净注射剂 275 替加环素注射剂 276 头孢吡肟注射剂型 277 阿加曲班注射剂 278 阿托西班注射剂 279 氨甲环酸注射剂型 280 氨氯地平阿托伐他汀口服常释剂型 281 丙氨酰谷氨酰胺注射剂 282 丙戊酸钠注射剂 283 非洛地平非洛地平Ⅱ缓释控释剂型 284 呋塞米注射剂 285 骨化三醇口服常释剂型 286 甲钴胺注射剂 287 奥司他韦干混悬剂 288 氯沙坦氢氯噻嗪口服常释剂型 289 米氮平口服常释剂型 290 那屈肝素(那曲肝素)注射剂 291 生长抑素注射剂 292 酮咯酸氨丁三醇注射剂 293 托拉塞米注射剂 294 熊去氧胆酸口服常释剂型 295 奥普力农注射剂 296 依诺肝素注射剂 297 左氨氯地平(左旋氨氯地平)口服常释剂型 298 左布比卡因注射剂 299 左卡尼汀注射剂 300 阿莫西林克拉维酸口服常释剂型 301 阿莫西林克拉维酸注射剂 302 氨曲南注射剂 303 奥硝唑注射剂型 304 复方磺胺甲噁唑口服常释剂型 305 甲硝唑注射剂型 306 利福平利福平Ⅱ口服常释剂型 307 头孢地尼颗粒剂 308 头孢西丁注射剂型 309 头孢地嗪注射剂 310 比阿培南注射剂 311 达托霉素注射剂 312 伏立康唑注射剂 313 哌拉西林他唑巴坦注射剂 314 头孢哌酮舒巴坦注射剂 315 头孢噻肟注射剂 申报时间及方式 企业及产品申报提交时间：2026年1月23日-2026年2月2日17时。 修改或补充材料时间：2026年1月23日-2026年2月3日17时前。 《公告》说明，未在相应规定的时间内完成申报提交和修改、补充材料的，视为放弃参与本次接续采购。截止时间如有调整，以后续公告为准。 近日热点阅读： 2026，医药代表的三大危机 只会“讲药”的医药代表，没有市场了 A司再度上榜！不服不行 勃林格荣膺“中国杰出雇主” 上药天普荣膺中国杰出雇主认证 医药行业三大央企披露高管年薪 安斯泰来蝉联“中国杰出雇主” 欧加隆蝉联“中国杰出雇主” 费卡中国连续荣膺中国杰出雇主 赵萍：跨国药企的“赢”，如何书写？ 一药企被诉拖欠研发费用 这些药企上榜创新药“华山奖” 通化东宝任命两名副总裁 日本药企2026涨薪幅度定了 医保支持创新，国产好药加速惠及患者 跨国药企裁员，近190名医药代表面临失业 明年3月，6000+医药精英赴约 西贝这事儿，医药老炮儿怎么处理？ 这家药企年会放大招！把医药人看酸了 中国医药又查一人 多家药企，高管变动 医药代表的五种类型，你属于哪一类？ 打通肥胖管理“最后一公里”，诺和诺德行动了 4个药品，暂停采购 年薪曾达870万元，一药企CEO辞职 医药巨头，再次补税三千多万 徐向平辞任九芝堂副总经理 拜耳中国12月热招岗位 费森尤斯卡比全国职位大放送 辉瑞中国成立新事业部，全国岗位 网红A司，风口加速扩招中 最新药企内部招聘（1月22日更新） #跨国药企在进博会 医药代表 伴您成长！

NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression.Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical records-derived dataset.Previously presented preliminary analysis of a 20,000 patient subset documented rapid resolution of depression and suicidality with initiation of intravenous ketamine.Analyses suggested that clinical response to intravenous ketamine is consistent with prior randomized trial data and compares favorably to currently-approved products.Results from an upcoming analysis of the full 70,000 patient Real World Data set will be presented to the FDA in support of Accelerated Approval. WILMINGTON, Del., Jan. 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has licensed Real World Evidence (RWE) drawn from over 70,000 patients in the United States who were treated with either intravenous ketamine or nasal S-ketamine for depression and suicidal ideation. The information is being submitted in support of NRx’s application for Accelerated Approval of NRX-100 (preservative-free ketamine) under Fast Track Designation for Treatment of Suicidal Ideation in Depression and Bipolar Depression. Currently, there is no medicine approved to treat suicidal ideation and the only FDA-approved treatment today is Electroshock Therapy. The RWE is provided by Osmind, a leading neuropsychiatry technology and medical records platform used by clinics across the United States. Through this collaboration, Osmind is supplying regulatory-grade real-world evidence (RWE) to the US Food and Drug Administration (FDA) to support NRx’s application for Accelerated Approval of NRX-100 (preservative-free ketamine) as a treatment for suicidal ideation in depression, including bipolar depression. Osmind offers an industry-leading real-world dataset on ketamine and esketamine with a large, diverse patient base and a comprehensive set of fit-for-purpose data variables spanning effectiveness and safety with longitudinal capture. This dataset includes nearly one million treatment sessions with ketamine or esketamine, hundreds of millions of datapoints of continuous vitals monitored during treatment, and differentiated data elements such as assessment of bladder symptoms and sedation. A preliminary analysis of a subset of patients was presented by Osmind at the 2024 meeting of the American Society of Clinical Psychopharmacology.1 Quantitative comparison to currently-approved products suggested a favorable clinical response. NRx is optimistic that when the full real-world dataset of over 70,000 patients is analyzed, the results will be clinically meaningful. In September 2025, FDA altered its policy to allow the submission of RWE that does not include personally-identifiable patient information, a policy shift that enables the submission of de-identified data from Osmind. “We appreciate Osmind’s partnership in sharing this 70,000 patient Real World dataset in support of NRX-100 approval by the FDA,” said Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals. “An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials. Ketamine has been adopted within the military and veterans communities for this purpose. As a result, only Americans whose care is paid for by the military and the Veterans Administration, along with those who can pay out of pocket, are able to access this potentially valuable medicine. Those who rely on other health insurance are generally not eligible for reimbursement. We are in the process of applying to the FDA for Accelerated Approval of NRX-100 (preservative-free ketamine) to enable broader access of this potentially life-saving medicine under appropriate medical supervision.” About NRx Pharmaceuticals, Inc.NRx Pharmaceuticals, Inc. (www.nrxpharma.com) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information:Brian KorbManaging Partner, astr partners(917) 653-5122brian.korb@astrpartners.com ___________________ 1 https://www.osmind.org/blog/esketamine-and-iv-ketamine-for-major-depression